Journal
JOURNAL OF THORACIC DISEASE
Volume 11, Issue -, Pages S71-S80Publisher
AME PUBL CO
DOI: 10.21037/jtd.2018.11.102
Keywords
Tumor mutational burden (TMB); immunotherapy; non-small cell lung cancer (NSCLC); tumor tissue; circulating tumor DNA
Categories
Funding
- French Government (National Research Agency, ANR) through the Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01]
- Conseil Departemental des Alpes Maritimes
- Ligue Departementale contre le Cancer
- Canceropole PACA
- Association for Cancer Research (ARC)
Ask authors/readers for more resources
In the last few years, the treatment of patients with non-small cell lung cancer (NSCLC) has impressively benefitted from immunotherapy, in particular from the inhibition of immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1). However, despite the significant survival benefit for some patients with advanced NSCLC, the objective response rates (ORRs) remain relatively low no more than 20-30% with a large proportion of patients demonstrating primary resistance. Although the selection of NSCLC patients for the first-line treatment is currently guided by the expression of PD-L1 in tumor cells as detected by immunohistochemistry, this is not the case for the second-line setting. Moreover, the sensitivity and specificity of PD-L1 expression is modest which has prompted the search for additional predictive biomarkers. In this context, the assessment of the tumor mutational burden (TMB), defined as the total number of nonsynonymous mutations in the coding regions of genes, has recently emerged as an additional powerful biomarker to select patients for immunotherapy. The purpose of our review is to highlight the recent advances as well as the challenges and perspectives in the field of TMB and immunotherapy for patients with NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available